One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a "non-poor prognosis" SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC.

Monia Marchetti

Arianna Ghirardi

Arianna Masciulli

Alessandra Carobbio

Francesca Palandri

Nicola Vianelli

Elena Rossi

Silvia Betti

Ambra Di Veroli

Alessandra Iurlo

Daniele Cattaneo

Guido Finazzi

Massimiliano Bonifacio

Luigi Scaffidi

Andrea Patriarca

Elisa Rumi

Ilaria Carola Casetti

Clemency Stephenson

Paola Guglielmelli

Elena Maria Elli

Miroslava Palova

Davide Rapezzi

Daniel Erez

Montse Gomez

Kai Wille

Manuel Perez‐Encinas

Francesca Lunghi

Anna Angona

Maria Laura Fox

Eloise Beggiato

Giulia Benevolo

Giuseppe Carli

Rossella Cacciola

Mary Frances McMullin

Alessia Tieghi

Valle Recasens

Susanne Isfort

Fabrizio Pane

Valerio De Stefano

Martin Griesshammer

Alberto Alvarez‐Larran

Alessandro Maria Vannucchi

Alessandro Rambaldi

Tiziano Barbui

American Journal of Hematology

《美国血液学杂志》广泛报道了人类血液疾病和人类疾病动物模型的实验和临床特征。该杂志发表在非恶性和恶性血液病方面的原创贡献，包括止血和血栓形成、免疫学、血库和干细胞生物学的临床和基础研究。欢迎和鼓励描述诊断和治疗血液疾病的新治疗方法的临床转化报告。该杂志包括常规的原创实验室和临床研究文章、简短的研究报告、批判性评论、血液学图像、信件和信件。

The American Journal of Hematology publishes extensive research on the experimental and clinical features of human blood diseases and their animal models. The journal features original contributions on both malignant and non-malignant hematological disorders, including clinical and basic research in hemostasis and thrombosis, immunology, blood banking, and stem cell biology. We welcome and encourage clinical translational reports that describe new diagnostic and therapeutic approaches for blood diseases. The journal includes regular original laboratory and clinical research articles, brief research reports, critical reviews, hematology images, letters, and other relevant content.

《美国血液学杂志》广泛报道人类血液疾病及其动物模型的实验和临床特征。该杂志发表关于非恶性和恶性血液病的原创研究，包括止血与血栓形成、免疫学、血库和干细胞生物学的临床与基础研究。我们欢迎并鼓励临床转化报告，描述诊断和治疗血液疾病的新方法。该杂志内容包括常规的原创实验室和临床研究文章、简短研究报告、批判性评论、血液学图像、信件及其他相关内容。

Second cancers in MPN: Survival analysis from an international study

SC is a relevant cause of death competing with MPN evolution and the role of cytoreductive and anti‐platelet drugs in modulating patient survival after the occurrence of a SC is confirmed.

MPN中的第二癌症：一项国际研究的生存分析

Category	Quartile
医学	1
医学, 血液学	2

Second cancers in MPN: Survival analysis from an international study

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info